'Egfr tki' presentation slideshows

Targeted Therapy for Metastatic NSCLC

Targeted Therapy for Metastatic NSCLC. Gregory J. Riely October 14, 2012. Disclosures. Consulting Chugai Ariad Tragara Daiichi Novartis Abbott Foundation Medicine Celgene. Research Funding Novartis Chugai Glaxo SmithKline BMS Infinity Pfizer Merck. Lung Adenocarcinomas.

880 views • 68 slides

Victor Cohen, MDCM, FRCPC Department of Oncology Segal Cancer Center

910 views • 62 slides

? ? ? ? ? ? ? ? ? ? V.1.1 2014

? ? ? ? ? ? ? ? ? ? V.1.1 2014. ???????? Revised on 2014/07/14. Multidisciplinary Team Taipei VGH Lung Cancer Panel Members TNM staging Taipei VGH supplement to TNM staging Table of stage grouping Evaluation and treatment Stage o (Tis)

1k views • 61 slides

in vivo animal model studies in biological science

in vivo animal model studies in biological science. Cancer 2. Neuroscience. Cancer research. 2. Neuroscience. Lung Cancer. Cure rate for all patients: 15%. Male. Female. EGFR Expression in NSCLC. Tumours showing high EGFR expression.

638 views • 50 slides

Il trattamento di prima linea nel paziente con mutazione EGFR Vanesa Gregorc

Il trattamento di prima linea nel paziente con mutazione EGFR Vanesa Gregorc Thoracic Oncology and Melanoma area coordinator IRCCS Ospedale San Raffaele Milano. Who should be tested for EGFR mutations?. Non-squamous NSCLC NSCLC NOS Adenosquamous NSCLC Squamous cell carcinoma if

517 views • 50 slides

New Strategies on Horizon

New Strategies on Horizon. Tony Mok MD Dept of Clinical Oncology The Chinse University of Hong Kong. Addressing the difference. TKI is forever. Novel Target. TKI is forever. 5cm. PR at 2cm. RECIST PD At 2.6cm. 0m. 6m. 12m. 18m. 5cm. PR at 2cm. Symptomatic PD at 4cm. 0m. 6m.

590 views • 48 slides

? ? ? ? ? ? ? ? ? ? V.2.0 2009

? ? ? ? ? ? ? ? ? ? V.2.0 2009. ???????? Revised on 2009/11/16 Released on 2009/11/23. Multidisciplinary Team Taipei VGH Lung Cancer Panel Members TNM staging Taipei VGH supplement to TNM staging Table of stage grouping Evaluation and treatment Stage o (Tis)

699 views • 42 slides

Gli inibitori di EGFR in associazione alla chemioterapia nei pazienti wild-type

CHEMO-IMMUNO-TARGET THERAPIES Tre strategie di trattamento nel NSCLC in stadio avanzato Camogli, 29-30 Aprile 2016. Gli inibitori di EGFR in associazione alla chemioterapia nei pazienti wild-type. Erika Rijavec UOS Tumori Polmonari Azienda Ospedaliera Universitaria San Martino IST

382 views • 36 slides

Acquired Resistance Patient Forum

Combinations for Treating EGFR Acquired Resistance. Melissa L. Johnson, MD. Acquired Resistance Patient Forum. In ALK, ROS1 & EGFR Lung Cancers. September 6, 2014 | Boston. Combination Treatments for EGFR Acquired Resistance. Dx : EGFR+ lung cancer. Acquired Resistance.

613 views • 27 slides

Acquired Resistance Patient Forum

Life After Erlotinib : What Next?. Jared Weiss Vice President, Cancergrace Assistant Professor of Medicine, UNC Lineberger Comprehensive Cancer Center. Acquired Resistance Patient Forum. In ALK, ROS1 & EGFR Lung Cancers. September 6, 2014 | Boston.

838 views • 25 slides

Development of Molecular Methodologies for the Enhanced Detection of Tumour Biomarkers

Development of Molecular Methodologies for the Enhanced Detection of Tumour Biomarkers. Michelle Wood , Hood Mugalassi, Justyna Tull, Linda Meredith, Rachel Butler Institute of Medical Genetics, University Hospital Wales, Cardiff. Lung cancer is the leading cause of cancer deaths.

468 views • 21 slides

First-Line TKI Use in EGFR Mutation-Positive NSCLC

400 views • 8 slides